{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:18Z","timestamp":1792078938359,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Psych"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40501-020-00233-9","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T21:02:42Z","timestamp":1599080562000},"page":"489-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacological Management of Neuropsychiatric Symptoms of Dementia"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-0150","authenticated-orcid":false,"given":"Lauren B.","family":"Gerlach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen C.","family":"Kales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"233_CR1","doi-asserted-by":"crossref","unstructured":"\u2022 Rozum WJ, Cooley B, Vernon E, Matyi J, Tschanz JT. Neuropsychiatric symptoms in severe dementia: Associations with specific cognitive domains the Cache County Dementia Progression Study. Int J Geriatr Psychiatry. 2019;34(7):1087\u201394 Prospective study evaluating the prevelance and types of neuropsychiatric symptoms experienced in patients with dementia.","DOI":"10.1002\/gps.5112"},{"key":"233_CR2","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","volume":"350","author":"HC Kales","year":"2015","unstructured":"\u2022\u2022 Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. Article highlighting the Describe, Investigate, Create, and Evaluate (DICE) non-pharmacological treatment approach to addressing behavioral disturbances in dementia.","journal-title":"BMJ"},{"issue":"3","key":"233_CR3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2190\/ABXK-FMWG-98YP-D1CU","volume":"33","author":"J Wancata","year":"2003","unstructured":"Wancata J, Windhaber J, Krautgartner M, Alexandrowicz R. The consequences of non-cognitive symptoms of dementia in medical hospital departments. Int J Psychiatry Med. 2003;33(3):257\u201371.","journal-title":"Int J Psychiatry Med."},{"issue":"16","key":"233_CR4","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1001\/jama.287.16.2090","volume":"287","author":"K Yaffe","year":"2002","unstructured":"Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287(16):2090\u20137.","journal-title":"JAMA."},{"issue":"1","key":"233_CR5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1093\/geronb\/55.1.S2","volume":"55","author":"LD Clyburn","year":"2000","unstructured":"Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H. Predicting caregiver burden and depression in Alzheimer\u2019s disease. J Gerontol B Psychol Sci Soc Sci. 2000;55(1):S2\u201313.","journal-title":"J Gerontol B Psychol Sci Soc Sci."},{"issue":"9","key":"233_CR6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1046\/j.1532-5415.2003.51415.x","volume":"51","author":"American Geriatrics Society","year":"2003","unstructured":"American Geriatrics Society. American Association of Geriatric Psyciatry. Consensus statement on improving the quality of mental health care in U.S. nursing homes: management of depression and behavioral symptoms associated with dementia. Journal of the American Geriatrics Society. 2003;51(9):1287\u201398.","journal-title":"Journal of the American Geriatrics Society."},{"key":"233_CR7","volume-title":"Five things physicians and patients should question","author":"Choosing Wisely","year":"2013","unstructured":"Choosing Wisely. Five things physicians and patients should question. Arlington (VA): American Psychiatric Association; 2013. Available at: http:\/\/www.choosingwisely.org\/societies\/american-psychiatric-association. Accessed Jun, 2020"},{"key":"233_CR8","doi-asserted-by":"crossref","unstructured":"\u2022 Maust DT, Kim HM, Chiang C, Kales HC. Association of the Centers for Medicare & Medicaid Services\u2019 National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014. JAMA Intern Med. 2018;178(5):640\u20137 Study evaluating recent psychotropic medication prescribing trends among Medicare beneficiaries with dementia in long-term care.","DOI":"10.1001\/jamainternmed.2018.0379"},{"key":"233_CR9","doi-asserted-by":"crossref","unstructured":"Maust DT, Strominger J, Bynum JPW, Langa KM, Gerlach LB, Zivin K, et al. Prevalence of psychotropic and opioid prescription fills among community-dwelling older adults with dementia in the U.S. JAMA. 2020; in press.","DOI":"10.1001\/jama.2020.8519"},{"key":"233_CR10","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38(5):553\u201363 This meta-analysis reviews the evidence for use of typical antipsychotics in treating neuropsychiatric symptoms.","DOI":"10.1111\/j.1532-5415.1990.tb02407.x"},{"key":"233_CR11","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596\u2013608 Comprehensive systematic review evaluating the use of pharmacotherapy in treatment of behavioral disturbances in dementia.","DOI":"10.1001\/jama.293.5.596"},{"key":"233_CR12","unstructured":"U.S. Food and Drug Administration. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. 2005. Available at: http:\/\/psychrights.org\/drugs\/FDAatypicalswarning4elderly.pdf Accessed on May 25, 2020."},{"key":"233_CR13","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210\u20136 The most recent meta-analysis examining the use of cholinesterase inhibitors in treating neuropsychiatric symptoms of dementia.","DOI":"10.1001\/jama.289.2.210"},{"issue":"4","key":"233_CR14","first-page":"546","volume":"6","author":"B Stotsky","year":"1984","unstructured":"Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther. 1984;6(4):546\u201359.","journal-title":"Clin Ther."},{"issue":"4","key":"233_CR15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1176\/jnp.9.4.591","volume":"9","author":"AP Auchus","year":"1997","unstructured":"Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci. 1997;9(4):591\u20133.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"3","key":"233_CR16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1099-1166(199703)12:3<319::AID-GPS488>3.0.CO;2-Q","volume":"12","author":"BA Lawlor","year":"1997","unstructured":"Lawlor BA, Aisen PS, Green C, Fine E, Schme\u00efdler J. Selegiline in the treatment of behavioural disturbance in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 1997;12(3):319\u201322.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"9","key":"233_CR17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","volume":"55","author":"L Teri","year":"2000","unstructured":"Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271\u20138.","journal-title":"Neurology."},{"issue":"3","key":"233_CR18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","volume":"159","author":"BG Pollock","year":"2002","unstructured":"Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460\u20135.","journal-title":"Am J Psychiatry."},{"issue":"10","key":"233_CR19","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/appi.ajp.157.10.1686","volume":"157","author":"CG Lyketsos","year":"2000","unstructured":"Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer\u2019s disease: initial results from the Depression in Alzheimer\u2019s Disease study. Am J Psychiatry. 2000;157(10):1686\u20139.","journal-title":"Am J Psychiatry."},{"issue":"1","key":"233_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","volume":"19","author":"SI Finkel","year":"2004","unstructured":"Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer\u2019s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19(1):9\u201318.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"12","key":"233_CR21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jagp.2013.12.174","volume":"22","author":"EF Camargos","year":"2014","unstructured":"Camargos EF, Louzada LL, Quintas JL, Naves JO, Louzada FM, N\u00f3brega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565\u201374.","journal-title":"Am J Geriatr Psychiatry."},{"key":"233_CR22","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391 The Citalopram for Agitation in Alzheimer\u2019s Disease (CitAD) study is the largest study evaluating the use of citalopram for treatment of neuropsychiatric symptoms of dementia.","DOI":"10.1001\/jama.2014.93"},{"key":"233_CR23","doi-asserted-by":"crossref","unstructured":"\u2022 Scoralick FM, Louzada LL, Quintas JL, Naves JO, Camargos EF, N\u00f3brega OT. Mirtazapine does not improve sleep disorders in Alzheimer\u2019s disease: results from a double-blind, placebo-controlled pilot study. Psychogeriatrics. 2017;17(2):89\u201396 Recent study evaluating use of mirtazapine in treating sleep disturbances in dementia.","DOI":"10.1111\/psyg.12191"},{"issue":"2","key":"233_CR24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0091-3057(95)00116-E","volume":"52","author":"JR McCarten","year":"1995","unstructured":"McCarten JR, Kovera C, Maddox MK, Cleary JP. Triazolam in Alzheimer\u2019s disease: pilot study on sleep and memory effects. Pharmacol Biochem Behav. 1995;52(2):447\u201352.","journal-title":"Pharmacol Biochem Behav."},{"issue":"4","key":"233_CR25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0893-133X(01)00365-7","volume":"26","author":"KM Meehan","year":"2002","unstructured":"Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26(4):494\u2013504.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"233_CR26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.155.1.54","volume":"155","author":"PN Tariot","year":"1998","unstructured":"Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54\u201361.","journal-title":"Am J Psychiatry."},{"issue":"4","key":"233_CR27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00019442-200111000-00008","volume":"9","author":"JT Olin","year":"2001","unstructured":"Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9(4):400\u20135.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"6","key":"233_CR28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gps.653","volume":"17","author":"RC Sival","year":"2002","unstructured":"Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry. 2002;17(6):579\u201385.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"11","key":"233_CR29","first-page":"942","volume":"13","author":"PN Tariot","year":"2005","unstructured":"Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005;13(11):942\u20139.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"2","key":"233_CR30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000097757","volume":"23","author":"N Herrmann","year":"2007","unstructured":"Herrmann N, Lanct\u00f4t KL, Rothenburg LS, Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2007;23(2):116\u20139.","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"2","key":"233_CR31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000199236","volume":"27","author":"OH Sommer","year":"2009","unstructured":"Sommer OH, Aga O, Cvancarova M, Olsen IC, Selbaek G, Engedal K. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord. 2009;27(2):155\u201363.","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"8","key":"233_CR32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","volume":"68","author":"PN Tariot","year":"2011","unstructured":"Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68(8):853\u201361.","journal-title":"Arch Gen Psychiatry."},{"key":"233_CR33","doi-asserted-by":"crossref","unstructured":"\u2022 Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242\u201354 Only study evaluating off-label use of dextromethorphan-quinidine for treatment of agitation in patients with Alzheimer disease.","DOI":"10.1001\/jama.2015.10214"},{"issue":"12","key":"233_CR34","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/gps.760","volume":"17","author":"M Serfaty","year":"2002","unstructured":"Serfaty M, Kennell-Webb S, Warner J, Blizard R, Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry. 2002;17(12):1120\u20137.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"4","key":"233_CR35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1272\/jnms.70.334","volume":"70","author":"K Asayama","year":"2003","unstructured":"Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70(4):334\u201341.","journal-title":"J Nippon Med Sch."},{"issue":"7","key":"233_CR36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/sleep\/26.7.893","volume":"26","author":"C Singer","year":"2003","unstructured":"Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer\u2019s disease. Sleep. 2003;26(7):893\u2013901.","journal-title":"Sleep."},{"issue":"22","key":"233_CR37","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1001\/jama.299.22.2642","volume":"299","author":"RF Riemersma-van der Lek","year":"2008","unstructured":"Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. Jama. 2008;299(22):2642\u201355.","journal-title":"Jama."},{"issue":"2","key":"233_CR38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","volume":"17","author":"PR Gehrman","year":"2009","unstructured":"Gehrman PR, Connor DJ, Martin JL, Shochat T, Corey-Bloom J, Ancoli-Israel S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry. 2009;17(2):166\u20139.","journal-title":"Am J Geriatr Psychiatry."},{"key":"233_CR39","first-page":"947","volume":"9","author":"AG Wade","year":"2014","unstructured":"Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer\u2019s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947\u201361.","journal-title":"Clin Interv Aging."},{"key":"233_CR40","doi-asserted-by":"crossref","unstructured":"\u2022 Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;(2):Cd002852 This meta-analysis evaluates the evidence for haloperidol in treating neuropsychiatric symptoms of dementia.","DOI":"10.1002\/14651858.CD002852"},{"issue":"5","key":"233_CR41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","volume":"25","author":"P De Deyn","year":"2005","unstructured":"De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer\u2019s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25(5):463\u20137.","journal-title":"J Clin Psychopharmacol."},{"issue":"3","key":"233_CR42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","volume":"14","author":"J Mintzer","year":"2006","unstructured":"Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006;14(3):280\u201391.","journal-title":"Am J Geriatr Psychiatry."},{"key":"233_CR43","unstructured":"\u2022\u2022 Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med. 2006;355(15):1525\u201338 The Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer\u2019s Disease (CATIE-AD) trial is one of the largest randomized controlled trials evaluating use of atypical antipsychotic medications for treatment of behavioral disturbances in dementia."},{"key":"233_CR44","doi-asserted-by":"crossref","unstructured":"\u2022 Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191\u2013210 This meta-analysis included 15 randomized controlled trials examining atypical antipsychotic use for treatment of neuropsychiatric symptoms of dementia.","DOI":"10.1097\/01.JGP.0000200589.01396.6d"},{"key":"233_CR45","doi-asserted-by":"crossref","unstructured":"Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 142(006):767\u201376.","DOI":"10.1097\/01.JGP.0000196628.12010.35"},{"issue":"17","key":"233_CR46","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","volume":"68","author":"R Kurlan","year":"2007","unstructured":"Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356\u201363.","journal-title":"Neurology."},{"issue":"11","key":"233_CR47","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","volume":"15","author":"JE Mintzer","year":"2007","unstructured":"Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918\u201331.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"1","key":"233_CR48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/156720507779939805","volume":"4","author":"KX Zhong","year":"2007","unstructured":"Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007;4(1):81\u201393.","journal-title":"Curr Alzheimer Res."},{"issue":"4","key":"233_CR49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/gps.1892","volume":"23","author":"D Paleacu","year":"2008","unstructured":"Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer\u2019s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 2008;23(4):393\u2013400.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"7","key":"233_CR50","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","volume":"16","author":"JE Streim","year":"2008","unstructured":"Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(7):537\u201350.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"1","key":"233_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jamda.2008.06.006","volume":"10","author":"SA Rappaport","year":"2009","unstructured":"Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer\u2019s, vascular, or mixed dementia. J Am Med Dir Assoc. 2009;10(1):21\u20137.","journal-title":"J Am Med Dir Assoc."},{"key":"233_CR52","unstructured":"\u2022 Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213\u201322 This recent study evaluates use of pimavanserin in treating neuropsychiatric symptoms of dementia."},{"issue":"6","key":"233_CR53","first-page":"368","volume":"42","author":"MP Cruz","year":"2017","unstructured":"Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson\u2019s disease. P T. 2017;42(6):368\u201371.","journal-title":"P T."},{"issue":"7","key":"233_CR54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.60.7.737","volume":"60","author":"CG Lyketsos","year":"2003","unstructured":"Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737\u201346.","journal-title":"Arch Gen Psychiatry."},{"issue":"1","key":"233_CR55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00019442-200102000-00009","volume":"9","author":"AP Porsteinsson","year":"2001","unstructured":"Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9(1):58\u201366.","journal-title":"Am J Geriatr Psychiatry."},{"key":"233_CR56","doi-asserted-by":"crossref","unstructured":"Gerlach LB, Kales HC, Kim HM, et al. Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011\u20132014. J Am Med Dir Assoc. 2020.","DOI":"10.1016\/j.jamda.2020.05.039"},{"key":"233_CR57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2018.05.019","volume":"71","author":"DP Devanand","year":"2018","unstructured":"Devanand DP, Strickler JG, Huey ED, et al. Lithium treatment for agitation in Alzheimer\u2019s disease (Lit-AD): clinical rationale and study design. Contemp Clin Trials. 2018;71:33\u20139.","journal-title":"Contemp Clin Trials."},{"issue":"2","key":"233_CR58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamainternmed.2018.6112","volume":"179","author":"M Fralick","year":"2019","unstructured":"Fralick M, Sacks CA, Kesselheim AS. Assessment of use of combined dextromethorphan and quinidine in patients with dementia or Parkinson disease after US Food and Drug Administration approval for pseudobulbar affect. JAMA Internal Medicine. 2019;179(2):224\u201330.","journal-title":"JAMA Internal Medicine."},{"key":"233_CR59","doi-asserted-by":"crossref","first-page":"a1227","DOI":"10.1136\/bmj.a1227","volume":"337","author":"IJ Douglas","year":"2008","unstructured":"Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.","journal-title":"BMJ."},{"issue":"12","key":"233_CR60","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jagp.2015.07.001","volume":"23","author":"A Vasudev","year":"2015","unstructured":"Vasudev A, Shariff SZ, Liu K, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004\u20132013. Am J Geriatr Psychiatry. 2015;23(12):1259\u201369.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"2","key":"233_CR61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/bmjqs-2018-007840","volume":"28","author":"NM Ivers","year":"2019","unstructured":"Ivers NM, Taljaard M, Giannakeas V, Reis C, Williams E, Bronskill S. Public reporting of antipsychotic prescribing in nursing homes: population-based interrupted time series analyses. BMJ Quality & Safety. 2019;28(2):121\u201331.","journal-title":"BMJ Quality & Safety."},{"issue":"11","key":"233_CR62","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","volume":"91","author":"M Markota","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016;91(11):1632\u20139.","journal-title":"Mayo Clin Proc."},{"key":"233_CR63","unstructured":"Centers for Medicare and Medicaid Services. Partnership to improve dementia care in nursing homes: antipsychotic drug use in nursing homes trend update. https:\/\/www.cms.gov\/Newsroom\/MediaReleaseDatabase\/Fact-sheets\/2014-Fact-sheets-items\/2014-09-19.html. Published 2014. Accessed Jun 1, 2020."},{"key":"233_CR64","doi-asserted-by":"crossref","unstructured":"\u2022 Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946\u201353 Meta-analysis evaluating non-pharmacological interventions including caregiver-focused interventions in addressing neuropsychiatric symptoms of dementia.","DOI":"10.1176\/appi.ajp.2012.11101529"},{"issue":"4","key":"233_CR65","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jgs.12730","volume":"62","author":"HC Kales","year":"2014","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Detroit Expert Panel on Assessment and Mangement of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762\u20139.","journal-title":"J Am Geriatr Soc."}],"container-title":["Current Treatment Options in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40501-020-00233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40501-020-00233-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40501-020-00233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:16:23Z","timestamp":1630538183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40501-020-00233-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1007\/s40501-020-00233-9","relation":{},"ISSN":["2196-3061"],"issn-type":[{"value":"2196-3061","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"2 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}